Australia has one of the most generous R&D tax incentives available for clinical trials globally. For companies with an annual turnover of less than A$20 Million, Australian government provides a cash refund of 43.5% tax credit and for companies with an annual turnover of over A$20 Million, a 38.5% non-refundable tax credit is available for eligible R&D expenditure.

Most clinical trials conducted in Australia ( Phase 0/I/II/III) are eligible for R&D tax incentive. While Phase IV are excluded, there are exceptions. If the Phase IV study is conducted to answer a key scentific question and not merely for regulatory requirements, the Phase IV study might become eligible for R&D tax incentive. Clinexa has the capability to advise clients on how to design their studies including Phase IV studies so that there is a high likelyhood for meeting the conditions of R&D tax incentive.

Clinexa partners with seasoned consulting companies to make it easy for offshore entities to set up the necessary corporate structure in Australia for becoming eligible for the appropriate tax credit.